Assessment of in vivo bone microarchitecture changes in an anti-TNFα treated psoriatic arthritic patient.

<h4>Objective</h4>Psoriatic arthritis (PsA) is an inflammatory rheumatic disease, mediated in part by TNFα and associated with bone loss. Anti-TNFα treatment should inhibit this phenomenon and reduce the systemic bone loss. Ultra-high field MRI (UHF MRI) may be used to quantify bone micr...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Enrico Soldati, Lucas Escoffier, Sophie Gabriel, Augustin C Ogier, Christophe Chagnaud, Jean P Mattei, Serge Cammilleri, David Bendahan, Sandrine Guis
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/18a89909cce04386831e5f130afaf1c2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:18a89909cce04386831e5f130afaf1c2
record_format	dspace
spelling	oai:doaj.org-article:18a89909cce04386831e5f130afaf1c22021-11-25T06:19:07ZAssessment of in vivo bone microarchitecture changes in an anti-TNFα treated psoriatic arthritic patient.1932-620310.1371/journal.pone.0251788https://doaj.org/article/18a89909cce04386831e5f130afaf1c22021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0251788https://doaj.org/toc/1932-6203<h4>Objective</h4>Psoriatic arthritis (PsA) is an inflammatory rheumatic disease, mediated in part by TNFα and associated with bone loss. Anti-TNFα treatment should inhibit this phenomenon and reduce the systemic bone loss. Ultra-high field MRI (UHF MRI) may be used to quantify bone microarchitecture (BM) in-vivo. In this study, we quantified BM using UHF MRI in a PsA patient and followed up the changes related to anti-TNFα treatment.<h4>Subjects and methods</h4>A non-treated PsA patient with knee arthritis and 7 gender-matched controls were scanned using a gradient re-echo sequence at UHF MRI. After a year of Adalimumab treatment, the patient underwent a second UHF MRI. A PET-FNa imaging was performed before and after treatment to identify and localize the abnormal metabolic areas. BM was characterized using typical morphological parameters quantified in 32 regions of interest (ROIs) located in the patella, proximal tibia, and distal femur.<h4>Results</h4>Before treatment, the BM parameters were statistically different from controls in 24/32 ROIs with differences reaching up to 38%. After treatment, BM parameters were normalized for 15 out of 24 ROIs. The hypermetabolic areas disclosed by PET-FNa before the treatment partly resumed after the treatment.<h4>Conclusion</h4>Thanks to UHF MRI, we quantified in vivo BM anomalies in a PsA patient and we illustrated a major reversion after one year of treatment. Moreover, BM results highlighted that the abnormalities were not only localized in hypermetabolic regions identified by PET-FNa, suggesting that the bone loss was global and not related to inflammation.Enrico SoldatiLucas EscoffierSophie GabrielAugustin C OgierChristophe ChagnaudJean P MatteiSerge CammilleriDavid BendahanSandrine GuisPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 5, p e0251788 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Enrico Soldati Lucas Escoffier Sophie Gabriel Augustin C Ogier Christophe Chagnaud Jean P Mattei Serge Cammilleri David Bendahan Sandrine Guis Assessment of in vivo bone microarchitecture changes in an anti-TNFα treated psoriatic arthritic patient.
description	<h4>Objective</h4>Psoriatic arthritis (PsA) is an inflammatory rheumatic disease, mediated in part by TNFα and associated with bone loss. Anti-TNFα treatment should inhibit this phenomenon and reduce the systemic bone loss. Ultra-high field MRI (UHF MRI) may be used to quantify bone microarchitecture (BM) in-vivo. In this study, we quantified BM using UHF MRI in a PsA patient and followed up the changes related to anti-TNFα treatment.<h4>Subjects and methods</h4>A non-treated PsA patient with knee arthritis and 7 gender-matched controls were scanned using a gradient re-echo sequence at UHF MRI. After a year of Adalimumab treatment, the patient underwent a second UHF MRI. A PET-FNa imaging was performed before and after treatment to identify and localize the abnormal metabolic areas. BM was characterized using typical morphological parameters quantified in 32 regions of interest (ROIs) located in the patella, proximal tibia, and distal femur.<h4>Results</h4>Before treatment, the BM parameters were statistically different from controls in 24/32 ROIs with differences reaching up to 38%. After treatment, BM parameters were normalized for 15 out of 24 ROIs. The hypermetabolic areas disclosed by PET-FNa before the treatment partly resumed after the treatment.<h4>Conclusion</h4>Thanks to UHF MRI, we quantified in vivo BM anomalies in a PsA patient and we illustrated a major reversion after one year of treatment. Moreover, BM results highlighted that the abnormalities were not only localized in hypermetabolic regions identified by PET-FNa, suggesting that the bone loss was global and not related to inflammation.
format	article
author	Enrico Soldati Lucas Escoffier Sophie Gabriel Augustin C Ogier Christophe Chagnaud Jean P Mattei Serge Cammilleri David Bendahan Sandrine Guis
author_facet	Enrico Soldati Lucas Escoffier Sophie Gabriel Augustin C Ogier Christophe Chagnaud Jean P Mattei Serge Cammilleri David Bendahan Sandrine Guis
author_sort	Enrico Soldati
title	Assessment of in vivo bone microarchitecture changes in an anti-TNFα treated psoriatic arthritic patient.
title_short	Assessment of in vivo bone microarchitecture changes in an anti-TNFα treated psoriatic arthritic patient.
title_full	Assessment of in vivo bone microarchitecture changes in an anti-TNFα treated psoriatic arthritic patient.
title_fullStr	Assessment of in vivo bone microarchitecture changes in an anti-TNFα treated psoriatic arthritic patient.
title_full_unstemmed	Assessment of in vivo bone microarchitecture changes in an anti-TNFα treated psoriatic arthritic patient.
title_sort	assessment of in vivo bone microarchitecture changes in an anti-tnfα treated psoriatic arthritic patient.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/18a89909cce04386831e5f130afaf1c2
work_keys_str_mv	AT enricosoldati assessmentofinvivobonemicroarchitecturechangesinanantitnfatreatedpsoriaticarthriticpatient AT lucasescoffier assessmentofinvivobonemicroarchitecturechangesinanantitnfatreatedpsoriaticarthriticpatient AT sophiegabriel assessmentofinvivobonemicroarchitecturechangesinanantitnfatreatedpsoriaticarthriticpatient AT augustincogier assessmentofinvivobonemicroarchitecturechangesinanantitnfatreatedpsoriaticarthriticpatient AT christophechagnaud assessmentofinvivobonemicroarchitecturechangesinanantitnfatreatedpsoriaticarthriticpatient AT jeanpmattei assessmentofinvivobonemicroarchitecturechangesinanantitnfatreatedpsoriaticarthriticpatient AT sergecammilleri assessmentofinvivobonemicroarchitecturechangesinanantitnfatreatedpsoriaticarthriticpatient AT davidbendahan assessmentofinvivobonemicroarchitecturechangesinanantitnfatreatedpsoriaticarthriticpatient AT sandrineguis assessmentofinvivobonemicroarchitecturechangesinanantitnfatreatedpsoriaticarthriticpatient
_version_	1718413907960266752

Assessment of in vivo bone microarchitecture changes in an anti-TNFα treated psoriatic arthritic patient.

Ejemplares similares